Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GU12-159

The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

  • Kim N. Chi, Mark T. Fleming, Katherine Sunderland, Costantine Albany, Joel Gingerich, Fred Saad, Scott A. North, Alexander Starodub, Richard C. Lauer, Joseph D. Ruether, Madelaine Miranda Sgroi, Mark C. Scholz, Christopher Sweeney; British Columbia Cancer Agency, Vancouver, BC, Canada; US Oncology Research, Virginia Oncology Associates, Hampton, VA; BC Cancer Centre, Vancouver, BC, Canada; Indiana University School of Medicine, Indianapolis, IN; CancerCare Manitoba, Winnipeg, MB, Canada; University of Montreal, Montreal, QC, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Indiana University Health Goshen Center for Cancer Care, Goshen, IN; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; Tom Baker Cancer Center, Calgary, AB, Canada; Central Indiana Cancer Center, Indianapolis, IN; Prostate Oncology Specialists, Marina del Rey, CA; Dana-Farber Cancer Institute, Boston, MA. PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI). Accepted to Poster Session A at the ASCO 2017 Genitourinary Cancers Symposium, February 16-18, 2017, Orlando, Fla. J Clin Oncol 35, 2017 (suppl 6S; abstract 146). See abstract.